Status:
TERMINATED
HFNC Vs LFNC in Patients with AF Undergoing RFCA Under Deep Sedation.
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Deep Sedation
Oxygen Therapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Oxygen supplementation through high flow nasal cannula (HFNC) may reduce the incidence of desaturation and hypoxemia during deep sedation at radiofrequency catheter ablation (RFCA procedures).This stu...
Detailed Description
Desaturation may occur in patients under deep sedation which results in an elevated risk for perioperative adverse events including hypoxemia (1-3). The incidence of hypoxemia was 168 per 1000 in a ge...
Eligibility Criteria
Inclusion
- Adults undergoing an elective RFCA for atrial fibrillation in the Maastricht UMC Cardiac Catheter Labs under deep sedation administered by a clinician anesthesiology
Exclusion
- Age under 18 years
- Body Mass Index (BMI) \> 32 kg/m²
- Diagnosed Sleep Apnoea Syndrome (SAS)
- Chronic Pulmonary Obstructive Disease (COPD) gold IV and COPD gold III with frequent or recent exacerbation
- Diagnosed pulmonary or cardiac condition requiring chronic oxygen therapy
- Complete nasal obstruction
- Active nose bleeding
- Untreated pneumothorax (pre- existing)
- Recent upper airway surgery
- Recent base of skull fracture
- Expected difficult airway
Key Trial Info
Start Date :
January 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2024
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT04842253
Start Date
January 4 2022
End Date
November 18 2024
Last Update
February 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht UMC
Maastricht, Netherlands, 6229HX